Sanofi drops plans to seek global approvals for amlitelimab in atopic dermatitis amid portfolio review

Reuters2026/07/24 05:32

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sanofi will stop clinical development of amlitelimab in moderate-to-severe atopic dermatitis, dropping plans for global regulatory submissions.
Portfolio review will redirect resources, citing an unfavorable efficacy-safety balance and no meaningful improvement versus standard of care in atopic dermatitis.
Ongoing atopic dermatitis studies will be wound down with site and regulator coordination to support patient care transitions.
2026 financial guidance remains unchanged despite the atopic dermatitis program termination.
Development continues in celiac disease, with phase 2 results expected in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sanofi drops plans to seek global approvals for amlitelimab in atopic dermatitis amid portfolio review

You may also like

Crypto prices